List view / Grid view
EPR’s Caroline Peachey explores collaborative efforts to accelerate validation and…
EPR’s Caroline Peachey explores collaborative efforts to accelerate validation and adoption of rapid microbial methods across the pharmaceutical industry.
In this Q&A Miriam Guest, Principal Microbiologist at AstraZeneca UK,…
In this Q&A Miriam Guest, Principal Microbiologist at AstraZeneca UK, discusses trends in bacterial endotoxin testing, as well as factors to consider when looking to implement rapid methods.
EPR Issue 1 includes articles on the future of pharmaceutical…
EPR Issue 1 includes articles on the future of pharmaceutical microbiology, separation and purification of complex biologics, the latest on nitrosamines and more...
Principal Microbiologist, New Modalities and Parenteral Development. Pharmaceutical Technology and…
20 January 2023 | By
Principal Microbiologist, New Modalities and Parenteral Development. Pharmaceutical Technology and Development, Global Operations, AstraZeneca UK.
Here, microbiology experts Tim Sandle, Tony Cundell and AstraZeneca’s Miriam…
Here, microbiology experts Tim Sandle, Tony Cundell and AstraZeneca’s Miriam Guest reflect on key developments in pharmaceutical microbiology during 2022.
How is the implementation of artificial intelligence, machine learning and…
How is the implementation of artificial intelligence, machine learning and virtual reality shaping the microbiology lab of the future? What do these innovations mean for personnel? Find out in this episode with AstraZeneca...
Features in this in-depth focus explore the development of a…
Features in this in-depth focus explore the development of a sustainable approach to bacterial endotoxin testing (BET) within a global enterprise, as well as progress towards the use of biofluorescent particle counters for water bioburden applications.
